Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COUP-1: Copanlisib and Rituximab in Marginal Zone Lymphoma
2022-500674-34-00Phase 2Authorised
- Sponsor
- University Hospital Ulm
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib and rituximab in marginal zone B-cell lymphoma (MZL), extranodal marginal zone B-cell lymphoma (EMZL), splenic marginal zone lymphoma (SMZL) and 1 more, sponsored by University Hospital Ulm. Primary endpoint: Complete response rate at 12 months. Planned start Sep 2024; status: authorised.
02
Drugs
copanlisibrituximab
03
Conditions
marginal zone B-cell lymphoma (MZL)extranodal marginal zone B-cell lymphoma (EMZL)splenic marginal zone lymphoma (SMZL)nodal marginal zone B-cell lymphoma (NMZL)
Beyond the preview
Go deeper on 2022-500674-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500674-34-00.